Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
about
SK-MEL-1SK-MEL-100SK-MEL-103SK-MEL-105SK-MEL-109SK-MEL-11SK-MEL-110SK-MEL-113SK-MEL-117SK-MEL-118SK-MEL-119SK-MEL-12SK-MEL-127SK-MEL-13SK-MEL-130SK-MEL-131SK-MEL-133SK-MEL-146SK-MEL-147SK-MEL-15SK-MEL-153SK-MEL-161SK-MEL-170SK-MEL-173SK-MEL-174SK-MEL-176SK-MEL-178SK-MEL-181SK-MEL-182SK-MEL-186SK-MEL-187SK-MEL-188SK-MEL-19SK-MEL-190SK-MEL-191SK-MEL-192SK-MEL-196SK-MEL-199SK-MEL-2SK-MEL-200
P1343
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesionsResistant mechanisms to BRAF inhibitors in melanomaTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?The GIST of targeted therapy for malignant melanomaImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeLoss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Perturbation biology: inferring signaling networks in cellular systemsRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsTransmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.Spatial normalization of reverse phase protein array data.A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.Discovery of co-occurring driver pathways in cancerMulti-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsThe stable traits of melanoma genetics: an alternate approach to target discoveryNovel somatic mutations to PI3K pathway genes in metastatic melanomaComplete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutationsPerturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer.Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.Genotyping of cutaneous melanoma.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanomaOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaActivating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.PTEN: Multiple Functions in Human Malignant TumorsInterferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma.A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategiesThe current state of targeted therapy in melanoma: this time it's personalRole of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathwaysSelective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanomaBRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsGlobal Conservation of Protein Status between Cell Lines and Xenografts
P2860
Q54953753-7334ED20-99E3-4584-9211-3BC0A4AECFB8Q54953756-F6E64191-AAAB-4CF9-9FCF-D0E59A461A8FQ54953761-747871AB-C6F6-433D-BCF1-797C855F2A21Q54953764-6AF75A7D-8356-4101-9D22-04BA36B37E54Q54953769-E89792D0-C7DA-4736-BD2B-007F451BDC81Q54953770-3FB80EFD-8646-4B21-AF5F-FE3C88CD10BDQ54953772-AB340E19-87D9-4B7A-8894-8C8FD1C5DC33Q54953776-13B8E13B-5985-4071-A867-3A92CEDC2854Q54953780-0562A821-62B5-48D4-9CA7-DABEB31025C7Q54953782-BAC7C934-2827-4B76-A18D-EAFCA0A212B2Q54953784-DDE79ED8-3EB1-4D14-8826-30A4FFDEF113Q54953785-E766AAC8-3108-488C-AB86-2805FDDE71E1Q54953809-3EED9AA9-8535-4AA9-8C85-672357355E8AQ54953813-8E4B5E47-4B60-4BCB-A2A6-9700B3924C6BQ54953814-FE0D4C36-CA87-40FD-8BAE-93A8F6B1B207Q54953816-E435B883-C4F5-49B5-AE7A-F6EB442AA11FQ54953819-716262F3-7E05-4662-AD47-299338A3B30FQ54953833-583DDB15-A1B0-49BE-9F6E-137AE47D5E64Q54953834-44DD66AE-EE72-482B-8D20-961D8596DD13Q54953835-83B0B002-DFA6-403C-A198-BB84C7E5CC54Q54953840-7D012ED6-EA8C-4BCA-BCBD-DB049B0EF112Q54953844-08E683EC-F008-4873-A771-AC735892F299Q54953858-D197E621-F9B5-4DC5-8329-227C8DCC513FQ54953860-07423D08-4152-4C4F-B06A-F7BC2CBFFA32Q54953862-977EFF28-CA6B-4486-BE12-FC13CC6CCEB9Q54953864-224CCAD5-7F34-49E9-AE7F-8CCC5D986DDFQ54953868-A8B31EED-65E1-40C5-81E0-F734753B63CEQ54953888-3A9D3E33-B1E6-4BEF-BED1-5C23E205B0E2Q54953889-5EC1EE2E-CFDD-457E-9B45-FEA81BE48CC0Q54953890-972998A3-EA31-488C-8ED7-C7CEC4D3BDC5Q54953892-E76DD38E-2A11-4FA3-A3DB-32C138D78319Q54953893-492D9A01-01DE-424B-90A3-FF9E1575F089Q54953894-C2089B7B-BF51-457A-8719-4A729237643FQ54953896-D53206C8-01E8-4667-AB43-566D125C5E28Q54953897-43C2AD0B-6DA1-442F-B2AC-1A778CC71CF1Q54953899-C34D45C3-89B0-4B78-AF8A-CB9904243C6FQ54953900-97EDA34D-1B67-40C7-BEAE-873F2EB4B464Q54953904-EBAEACC1-C4B3-4B02-817B-AC8D3A80A687Q54953905-928151A8-40E2-48AE-A454-C98E241B1D3BQ54953910-37E7B3F4-43AB-44B7-A70B-9C0FB1F01347
P1343
Q21004109-08610B79-E08B-4185-97F8-A4A762311356Q26739717-C528F07B-4ACC-4DD1-BEA3-811938D30545Q26782222-2DFCCABB-10BF-4231-A924-A959FC9BD6F2Q26827092-BCA1464A-CF8C-491D-8D45-0715858A0EFBQ27334924-51D5A7B5-4778-43D7-BFC7-73D56C5E4C74Q27852894-6702F3E0-AAFB-407F-8DE3-441FC3BB8496Q28537769-E03EB624-8F96-4D42-B9C4-BCD33769B20FQ28730438-55FD95FC-8F5B-4C2A-8E90-A3DA89BBDB7EQ30787310-A287F680-DFD8-42D8-A78A-0699CFA2713CQ30877911-A6393CDA-8665-44C9-9670-8918B4CFCED0Q33875566-4B75B4DD-133A-42D2-9D19-B773620C9681Q34048409-7252D3CD-5302-4874-A21B-75CB80B5BB02Q34098286-74531090-19C2-4F0B-BDFD-31BF1F2CB653Q34165045-7B295E11-7210-4B9F-9F89-AB8193EBFFD1Q34248355-2935DEDA-C11F-47E3-90B5-3869826E559DQ34389570-18FC349C-5871-487D-A88C-45796F4FCAB4Q34438555-3182D73F-3239-4558-BD17-5CA90E414CDAQ34489987-4AC9271D-AE11-4ABF-8947-61768E30035AQ34532230-6998E0A9-6DF9-4B1C-B842-5053D649ECC3Q34602664-3287029D-3B48-4317-A905-4C05043EDBFDQ34667738-47D2222C-EE81-416C-8B4A-4E89131E0337Q34667825-9F230FE4-2405-417E-B96D-FB380E4BAF47Q34669746-D8752C94-AD32-4D40-BFAD-6AACDD533ACAQ34786402-3736D14B-3EE8-4216-A746-402A6348944FQ35033377-9CBABC4A-0495-4C21-905E-314DDC8E0DF5Q35087328-375032F4-9FDA-48EB-A514-9F3791F8C402Q35164197-C0E6FE03-D9C1-4718-856F-0EA3A9037BAEQ35820476-3FDD16B4-E932-49EA-B9BB-3729A2EAFE1FQ35859282-DDEDF2DC-4060-4E12-AA97-2B33F8D70815Q35878248-3E542F1F-A83E-4503-8956-2A050C609A61Q36184769-C58FE491-0129-49C1-B000-64884360B627Q36194822-E3EFEEF4-D46F-40BC-AB17-C82EEE88AE9FQ36289114-579F6883-218D-44CF-83CF-EA661D29B361Q36346641-51078B03-9E85-4308-88DB-6C0561FF4E04Q36373537-A92987F7-78DC-4792-9253-FD6B83730F15Q36553576-22F75551-F176-40C1-8D9C-0943B5793AF1Q36793441-8F8566A3-AF9F-469C-A87C-8E5E27716ADFQ36833326-0F31EA8E-ED96-4D70-8115-B61446458C42Q36916468-746FA878-586C-4B2E-BDDB-957FA62ADA12Q37221907-A9BA2CFF-53DD-48C7-B4B8-076A3E3AB872
P2860
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Concurrent loss of the PTEN an ...... elanomas harboring (V600E)BRAF
@ast
Concurrent loss of the PTEN an ...... elanomas harboring (V600E)BRAF
@en
type
label
Concurrent loss of the PTEN an ...... elanomas harboring (V600E)BRAF
@ast
Concurrent loss of the PTEN an ...... elanomas harboring (V600E)BRAF
@en
prefLabel
Concurrent loss of the PTEN an ...... elanomas harboring (V600E)BRAF
@ast
Concurrent loss of the PTEN an ...... elanomas harboring (V600E)BRAF
@en
P2093
P2860
P4510
P356
P1433
P1476
Concurrent loss of the PTEN an ...... elanomas harboring (V600E)BRAF
@en
P2093
A Houghton
B S Taylor
C A Pratilas
D Cobrinik
E De Stanchina
P2860
P2888
P304
P356
10.1038/ONC.2011.250
P407
P4510
P577
2011-07-04T00:00:00Z